Dissecting the Basis of Nongenomic Activation of Endothelial Nitric Oxide Synthase by Estradiol: Role of ER{alpha} Domains with Known Nuclear Functions

Ken L. Chambliss1, Liliana Simon1, Ivan S. Yuhanna, Chieko Mineo and Philip W. Shaul

Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390

Address all correspondence and requests for reprints to: Philip W. Shaul, Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75390. E-mail: philip.shaul{at}utsouthwestern.edu.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Estradiol stimulates endothelial nitric oxide synthase (eNOS) via the activation of plasma membrane (PM)-associated estrogen receptor (ER) {alpha}. The process requires Src and erk signaling and eNOS phosphorylation by phosphoinositide 3-kinase (PI3 kinase)-Akt kinase, with Src and PI3 kinase associating with ER{alpha} upon ligand activation. To delineate the basis of nongenomic eNOS stimulation, the potential roles of ER{alpha} domains necessary for classical nuclear function were investigated in COS-7 cells. In cross-linking studies, estradiol-17ß (E2) caused PM-associated ER{alpha} to form dimers. However, eNOS activation by E2 was unaltered for a dimerization-deficient mutant ER{alpha} (ER{alpha}L511R). In contrast, ER{alpha} mutants lacking the nuclear localization signals (NLS), NLS2,3 (ER{alpha}{Delta}250–274) or the DNA binding domain (ER{alpha}{Delta}185–251), which targeted normally to PM and caveolae/rafts, were incapable of activating eNOS. The loss of NLS2/NLS3 prevented Src and erk activation, and it altered ligand-induced PI3 kinase-ER{alpha} interaction and prevented eNOS phosphorylation. Loss of the DNA binding domain did not change E2 activation of Src or erk, but ligand-induced PI3 kinase-ER{alpha} binding and eNOS phosphorylation did not occur. Thus, dimerization is not required for ER{alpha} coupling to eNOS; however, NLS2/NLS3 plays a role in Src activation, and the DNA binding region is involved in the dynamic interaction between ER{alpha} and PI3 kinase.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
CLINICAL AND LABORATORY studies indicate that estrogen has a marked impact on the response to vascular injury and the development of atherosclerosis. Many of these cardiovascular protective effects are due to nongenomic actions of the hormone on the vascular wall (1, 2), and a major role is played by the activation of nitric oxide (NO) (1) production by the endothelial isoform of NO synthase (eNOS) (3). Further work has demonstrated that both isoforms of the estrogen receptor (ER), ER{alpha} and ERß, mediate nongenomic eNOS activation (4, 5). In the classical model of nuclear ER action, the binding of estrogen releases receptors from inactive complexes containing heat shock proteins and immunophilins, and it induces receptor dimerization and binding to estrogen response elements (ERE) on target genes, thereby altering rates of gene transcription (6, 7, 8). ERs can also modulate gene expression in the absence of direct DNA binding via protein-protein interactions with other transcription factors (8, 9). However, there are also subpopulations of the receptors that are localized to the plasma membrane (PM) of numerous cell types, including endothelial cells, where they mediate membrane-initiated signaling (10, 11). On the PM of endothelial cells, both ER{alpha} and ERß are coupled to eNOS in caveolae, which are a subset of lipid rafts known to compartmentalize signaling molecules (5, 12).

Although the processes linking estrogen binding to ER and eNOS stimulation are complex, a degree of clarity has been afforded by prior knowledge of the multiple mechanisms mediating the activity of the enzyme. Numerous stimuli impact upon eNOS by activating kinases that alter the phosphorylation of the enzyme. Akt kinase stimulates eNOS by directly phosphorylating the enzyme at Ser-1179, and Akt itself is phosphorylated and activated by phosphoinositide 3-kinase (PI3 kinase), which is activated by both receptor and nonreceptor tyrosine kinases. In addition, eNOS is modulated by erk MAPKs, which can have either positive or negative effects on enzyme function (13, 14). As for estrogen-induced stimulation of eNOS, studies have shown that it entails signaling by erks and PI3 kinase/Akt kinase, and there is also evidence of an upstream role for Src kinase (4, 15, 16, 17, 18). Direct interaction has been reported between ER{alpha} and the p85{alpha} subunit of PI3 kinase with ligand activation of the receptor (16), there is evidence that c-Src, ER{alpha}, and PI3 kinase form a complex upon ligand activation (18), and it has been demonstrated that ER{alpha} modulation of eNOS also involves receptor interaction with G{alpha}i (19). Thus, certain aspects of the proximal mechanisms by which ER{alpha} are coupled to eNOS have been elucidated. However, the functional roles of ER{alpha} domains in signaling to eNOS are yet to be determined.

To further delineate the basis of nongenomic activation of eNOS by estrogen, the present investigation evaluated the role of ER{alpha} domains which are critical to classical nuclear function. This approach was chosen in an effort to distinguish domains which are uniquely relevant to membrane vs. nuclear ER{alpha} actions. Like other steroid hormone receptors, ER{alpha} has six structural regions designated A-F. The DNA binding domain is in region C, and the ligand binding domain is in region E. The other regions are the hypervariable A/B domain, the hinge region D, and the C-terminal F domain (6). The primary estrogen-inducible dimerization signal is in region E (20). Paralleling the features of ER{alpha} involved in classical nuclear action, we first tested the hypothesis that receptor dimerization is not required for estrogen-induced stimulation of eNOS. In addition, we determined whether domains within the two key nuclear localization signals (NLS) of ER{alpha}, which reside within the DNA binding domain and hinge region (21), play a role in eNOS activation. Furthermore, we determined whether domains within the DNA binding region of the receptor are involved in eNOS activation. Based on reports that the ligand binding domain of ER{alpha} is sufficient to mediate certain nonnuclear actions of estrogen (22, 23), the hypothesis raised was that the NLS and DNA binding domains are not required for estrogen-induced stimulation of eNOS.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Documenting Nuclear Functions
The functions of the domains of ER{alpha} involved in receptor dimerization, nuclear localization, and DNA binding were first confirmed in the COS-7 cell model system. The capacity to mediate estrogen-induced transcriptional transactivation was compared between wild-type ER{alpha} and ER{alpha}L511R using the estrogen-responsive reporter plasmid 2ERE-Luc (Fig. 1AGo). Whereas 2ERE-Luc reporter activity was increased by 4- to 5-fold with estradiol-17ß (E2) in cells expressing wild-type receptor, and the response was prevented by ER antagonism, reporter activity was not stimulated by the hormone in cells expressing ER{alpha}L511R. The abilities of ER{alpha}{Delta}250–274 and ER{alpha}{Delta}185–251 to mediate transcriptional transactivation were evaluated using the 3ERE-Luc reporter plasmid (Fig. 1BGo). In these experiments, there was a 9-fold increase in reporter activity with E2 in cells expressing wild-type receptor that was attenuated by ICI 182,780; in contrast, reporter activity was not stimulated by E2 in cells expressing either ER{alpha} mutant.



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1. ERE-Mediated Gene Transcription by Wild-Type and Mutant Forms of ER{alpha} in COS-7 Cells

Cells were cotransfected with receptor constructs and either 2ERE-Luc (A) or 3ERE-Luc (B) luciferase reporter plasmids, and reporter activity was determined after exposure to basal media, 10–8 M E2, or 10–8 M E2 + 10–5 M ICI 182,780 for 48 h. Reporter activity is expressed as luciferase activity/ß-galactosidase activity (Luc/ß-gal). Values are mean ± SEM, n = 4. *, P < 0.05 vs. basal; {dagger}, P < 0.05 vs. E2 alone. Similar findings were obtained in three independent experiments.

 
ER{alpha} dimerization was assessed by immunoblot analysis after cell treatment with E2 and either vehicle or the permeable cross-linking agent EDAC (Fig. 2). With wild-type receptor, a 67-kDa species indicative of ER{alpha} monomer was principally observed in the absence of cross-linker treatment, and a 134-kDa species of proper size to represent receptor dimer was also evident in cross-linker-treated cells (Fig. 2AGo). Similar experiments were done with truncated forms of ER{alpha} to confirm the detection of dimers using this approach. With ER{alpha}{Delta}185–251, a 58-kDa band indicative of monomer was detected in vehicle-treated cells, and a 116-kDa band of proper size to be dimerized mutant was also observed after cross-linker treatment. To provide another ER{alpha} construct of different size, the dimerization of an N-terminal deletion mutant (ER{alpha}{Delta}1–175) was evaluated. In the absence of EDAC, a 47-kDa monomeric form was detected by immunoblot analysis; after cross-linker treatment, a 94-kDa species was also detected of proper size to represent dimer. The attenuated capacity of ER{alpha}L511R to dimerize was then evaluated in a similar manner (Fig. 2BGo). Whereas wild-type receptor displayed a 134-kDa species upon cross-linker treatment, such a band was absent in studies of ER{alpha}L511R.



View larger version (27K):
[in this window]
[in a new window]
 
Fig. 2. Assessment of ER{alpha} Dimer Formation by Cross-Linking and Immunoblot Analysis

COS-7 cells were transiently transfected with cDNAs for wild-type ER{alpha}, ER{alpha} {Delta}185–251 or ER{alpha} {Delta}1–175 (A), or for wild-type or ER{alpha} L511R (B), and 48 h after transfection were treated with 10–8 M E2 for 24 h. Cells were then exposed to either vehicle or the cross-linking agent EDAC (10 mM for 60 min at 22 C), whole cell lysates were obtained, and immunoblot analysis for ER{alpha} was performed. C, PM-associated ER{alpha} form dimers upon ligand activation. COS-7 cells were transiently transfected with wild-type ER{alpha} cDNA, and 48 h after transfection were treated with 10–8 M E2 for 0 to 24 h. Cells were then exposed to vehicle or EDAC, whole cell lysates and purified PMs were obtained, and immunoblot analysis for ER{alpha} was performed. D, PM-associated ER{alpha}L511R does not form dimers. COS-7 cells were transiently transfected with wild-type ER{alpha} or ER{alpha}L511R, and 48 h after transfection were treated with vehicle or 10–8 M E2 for 1 h. Cells were then exposed to EDAC, whole cell lysates and PMs were obtained, and immunoblot analysis for ER{alpha} was performed. In A–D, dimers are indicated by arrowheads. Results shown are representative of three independent studies.

 
ER{alpha} Dimerization and eNOS Activation
Experiments were then performed to determine whether PM-associated ER{alpha} undergo dimerization upon ligand activation. COS-7 cells transfected with wild-type receptor were treated with E2 for 0–24 h and also with either vehicle or EDAC, whole cell lysates and purified PM fractions were obtained, and dimerization was assessed by immunoblot analysis. In samples of whole cell lysates from cross-linker-treated cells, a 134-kDa species was apparent after E2 treatment for 20 min or longer (Fig. 2CGo, upper panel). In a similar manner, PM fractions from EDAC-treated cells displayed a 134-kDa band after E2 exposure for 20 min or longer (Fig. 2CGo, lower panel). The capacity of wild-type ER{alpha} and ER{alpha}L511R to form dimers on the PM was also compared. Transfected COS-7 cells were treated with vehicle or E2 for 1 h followed by EDAC treatment. Whereas wild-type ER{alpha} displayed a 134-kDa species greatest in abundance with E2 in whole cell lysate and PM, such bands were negligible for both whole cell lysate and PM in studies of ER{alpha}L511R (Fig. 2DGo).

The role of dimerization in estrogen-induced activation of eNOS was determined in studies of COS-7 cells expressing eNOS and either wild-type ER{alpha} or ER{alpha}L511R (Fig. 3Go). To evaluate the localization of wild-type or mutant receptor coupling to eNOS (12), the activation of the enzyme was assessed in both intact cells and in isolated PMs obtained from the transfected cells. In intact cells expressing wild-type receptor, E2 caused a 2-fold increase in NOS activity, and the stimulation was completely prevented by concomitant treatment with ICI 182,780 (Fig. 3AGo). Similarly, in intact cells expressing ER{alpha}L511R, E2 treatment resulted in a 2.6-fold stimulation of eNOS that was blocked by ER antagonism. In a parallel manner, E2 caused a doubling in eNOS activity in PMs isolated from cells expressing wild-type receptor, and 2.4-fold stimulation was evident in PMs from cells expressing ER{alpha}L511R (Fig. 3BGo).



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3. Dimerization Is Not Required for ER{alpha} Modulation of eNOS Activity

COS-7 cells were transiently cotransfected with eNOS cDNA and cDNA for either wild-type ER{alpha} or ER{alpha} L511R, and 48 h later NOS activation was evaluated in either intact cells (A) or isolated PMs (B). For studies in intact cells, 3H-L-arginine conversion to 3H-L-citrulline was determined during 15-min incubations under basal conditions or in the presence of 10–8 M E2 or E2 plus 10–5 M ICI 182,780. For experiments using isolated PMs, 3H-L-citrulline generation was determined during 60-min incubations under basal conditions or with treatment with 10–8 M E2 or E2 plus 10–5 M ICI 182,780. Values are mean ± SEM, n = 4. *, P < 0.05 vs. basal; {dagger}, P < 0.05 vs. E2 alone. Results shown were confirmed in three separate experiments.

 
ER{alpha} Nuclear Localization Signals and eNOS Activation
The domains of ER{alpha} mediating the coupling of the receptor to eNOS are yet to be clarified. To determine whether residues within the principal nuclear localization signals, NLS 2 and 3, are involved, the PM association of ER{alpha}{Delta}250–274 was first evaluated. COS-7 cells were transfected with either wild-type ER{alpha} or the mutant form, and the relative abundance of ER{alpha} protein in the PM fraction vs. whole cell lysate was determined by immunoblot analysis using equal protein loads. Per unit of protein, wild-type receptor was approximately one third as prevalent in the PM as in whole cell lysate (Fig. 4AGo). Similar findings were obtained for ER{alpha}{Delta}250–274. When repeated studies were performed, the PM abundance per unit of protein relative to that in whole cell lysate was found to be similar for wild-type ER{alpha} and ER{alpha}{Delta}250–274 (Fig. 4BGo).



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 4. ER{alpha} Mutants Lacking NLS2,3 or the DNA Binding Domain Are Targeted Normally to the PM

COS-7 cells were transiently transfected with cDNA for wild-type ER{alpha} or for ER{alpha} {Delta}250–274 or ER{alpha} {Delta}185–251, and 48 h later whole cell lysates (WC) and purified PMs were obtained and the relative distribution of ER{alpha} protein was assessed by immunoblot analysis using equal protein loads of WC and PM (A). In B, cumulative findings for ER{alpha} abundance per unit of PM protein relative to abundance per unit of WC protein are shown for four independent studies. Values are mean ± SEM, normalized to relative PM vs. WC abundance for wild-type ER{alpha}.

 
Having observed that the NLS2,3-deficient mutant is localized to the PM in a manner that is comparable with wild-type receptor, the capacity of the mutant to mediate estrogen-induced activation of eNOS was determined in COS-7 cells coexpressing eNOS (Fig. 5Go). As already shown in Fig. 3Go, E2 caused a 2-fold increase in NOS activity in intact cells expressing wild-type receptor, and the response was completely prevented by concomitant treatment with ICI 182,780 (Fig. 5AGo). In contrast, in intact cells expressing ER{alpha}{Delta}250–274, E2 did not stimulate eNOS activity. In a parallel manner, E2 caused a doubling in eNOS activity in PMs from cells expressing wild-type receptor, but no stimulation was evident in PMs from cells expressing the NLS2,3-deficient mutant receptor (Fig. 5BGo).



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 5. Domains within NLS2 and NLS3 and the DNA Binding Region Are Required for ER{alpha} Modulation of eNOS Activity

COS-7 cells were transiently cotransfected with eNOS cDNA and cDNA for either wild-type ER{alpha}, ER{alpha} {Delta}250–274 or ER{alpha} {Delta}185–251, and 48 h later NOS activation was evaluated in either intact cells (A) or isolated PMs (B). For studies in intact cells, 3H-L-arginine conversion to 3H-L-citrulline was determined during 15-min incubations under basal conditions or with treatment with 10–8 M E2 or E2 plus 10–5 M ICI 182,780. For experiments using isolated PMs, 3H-L-citrulline generation was determined during 60-min incubations under basal conditions or with treatment with 10–8 M E2 or E2 plus 10–5 M ICI 182,780. Findings for wild-type ER{alpha} are the same as those reported in Fig. 3Go. Values are mean ± SEM, n = 4. *, P < 0.05 vs. basal; {dagger}, P < 0.05 vs. E2 alone. Results shown were confirmed in three separate experiments.

 
ER{alpha} DNA Binding Domain and eNOS Activation
The DNA binding region of ER{alpha} is critical to many nuclear actions of the receptor (6). However, it is not known whether residues within the DNA binding domain are involved in ER{alpha} mediation of eNOS activity. This question was first approached by evaluating the PM localization of ER{alpha}{Delta}185–251. After transient transfection in COS-7 cells, the mutant receptor was approximately one third as prevalent per unit of protein in the PM fraction as in the whole cell lysate, mimicking the relative distribution of wild-type receptor (Fig. 4Go). Because PM localization was retained by this mutant, the ability to mediate estrogen-induced activation of eNOS was determined in studies of COS-7 cells coexpressing eNOS (Fig. 5Go). Whereas E2 caused a 2-fold increase in NOS activity in intact cells expressing wild-type receptor that was blocked by ICI 182,780, cells expressing ER{alpha}{Delta}185–251 were unresponsive (Fig. 5AGo). Similarly, E2 stimulated eNOS activity in PMs from cells expressing wild-type ER{alpha}, but no activation occurred in PMs from cells expressing the mutant receptor lacking the DNA binding domain (Fig. 5BGo).

Bases for ER{alpha} Mutant Inactivity
Further experiments were performed to determine the bases by which ER{alpha}{Delta}250–274 and ER{alpha}{Delta}185–251 are incapable of eNOS activation. Having previously demonstrated that ER{alpha} coupling to eNOS occurs in caveolae, which are a subset of lipid rafts (12), the possibility was tested that the deletions perturb the targeting of the receptor to this specific microdomain. COS-7 cells were transfected with wild-type or mutant forms of ER{alpha}, whole cell lysates and purified PMs were obtained, caveolae subfractions of the PM were isolated, and the distribution of receptor protein was evaluated by immunoblot analysis. Wild-type ER{alpha} was detected in both whole PM and caveolae membranes (CM) (Fig. 6). ER{alpha}{Delta}250–274 and ER{alpha}{Delta}185–251 displayed a distribution within the PM that was comparable with that of wild-type receptor. ER{alpha}L511R showed a similar distribution (data not shown). After correction for the efficiency of membrane subfraction recovery, the distribution of wild-type and mutant receptors were quantitated (Table 1Go). A total of 7.3–11.0% of total cellular receptors were localized to the PM, 0.12–0.28% were localized to CMs, and there were no differences in the distribution of wild-type and mutant receptors.


View this table:
[in this window]
[in a new window]
 
Table 1. Wild-Type and Mutant ER{alpha} Abundance in PM and CM

 
Cumulative studies of signaling events proximal to eNOS indicate that enzyme stimulation by E2 entails erk activation and PI3 kinase/Akt kinase-mediated phosphorylation of the enzyme (3). To further determine the basis for the inability of ER{alpha}{Delta}250–274 and ER{alpha}{Delta}185–251 to stimulate eNOS, the capacities of the mutants to activate these processes were evaluated. As expected, erk activation and eNOS phosphorylation occurred within minutes of E2 treatment of cells expressing wild-type receptor (Fig. 7AGo). In contrast, negligible erk activation or eNOS phosphorylation was observed with E2 exposure of cells expressing ER{alpha}{Delta}250–274. However, the mutant of ER{alpha} lacking the DNA binding region (ER{alpha}{Delta}185–251) was capable of mediating erk activation, but eNOS phosphorylation was not detected. These findings were confirmed in additional quantitative studies of erk phosphorylation (Fig. 7BGo) and eNOS phosphorylation (Fig. 7CGo) at 10 min of E2 treatment. In additional experiments in cells expressing ER{alpha}{Delta}250–274 or ER{alpha}{Delta}185–251, the coexpression of a constitutively active mutant form of Akt resulted in levels of eNOS phosphorylation, which were at least comparable with those seen with E2 activation of wild-type receptor (Fig. 8AGo). In contrast, the coexpression of constitutively active Akt did not alter the level of erk activation in cells expressing either wild-type or mutant receptor forms (Fig. 8BGo).



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 7. ER{alpha} Domains Involved in Nuclear Localization and DNA Binding Are Required for Kinase Signaling Upstream of eNOS

COS-7 cells were transiently transfected with eNOS cDNA and cDNA for either wild-type ER{alpha}, ER{alpha} {Delta}250–274 or ER{alpha} {Delta}185–251, and 48 h later treated with 10–8 M E2 for 0–20 min (A). Cell lysates were analyzed by immunoblot using anti phospho-erk polyclonal antibody (perk), anti-erk2 monoclonal antibody (erk2), anti-phospho-Ser-1179 eNOS polyclonal antibody (peNOS), or anti-eNOS monoclonal antibody (eNOS). Additional experiments entailed E2 treatment for 10 min and quantitation of perk relative to erk (B) or peNOS relative to eNOS signal (C). Cumulative results expressed as percent of basal phosphorylation are shown for three independent studies (mean ± SEM; *, P < 0.05 vs. basal).

 


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 8. ER{alpha} Domains Involved in Nuclear Localization and DNA Binding Are Required for PI3 Kinase-Akt Kinase-Mediated Signaling

COS-7 cells were transiently transfected with eNOS cDNA and cDNA for either wild-type ER{alpha}, ER{alpha} {Delta}250–274, or ER{alpha} {Delta}185–251. In panels A and B, the cells were also cotransfected with empty vector or a constitutively active mutant form of Akt kinase (cAkt), and 48 h later treated with vehicle or 10–8 M E2 for 10 min. Cell lysates were analyzed by immunoblot using anti phospho-Ser-1179 eNOS polyclonal antibody (peNOS) or anti-eNOS monoclonal antibody (A), or using anti phospho-erk polyclonal antibody (perk) or anti erk2 monoclonal antibody (erk2) (B). Findings shown are representative of three independent studies.

 
The basis for ineffective erk or PI3 kinase activation by ER{alpha}{Delta}250–274 and ER{alpha}{Delta}185–251 was then investigated. Prior works indicate that E2 binding to membrane ER{alpha} leads to direct interaction between ER{alpha}, Src, and the p85 subunit of PI3 kinase, Src activation and Src-dependent PI3 kinase activation (16, 18). In studies evaluating Src activation (Fig. 9Go, A and B), E2 treatment of cells expressing wild-type ER{alpha} caused Src phosphorylation as expected. Src activation was also evident with E2 in cells expressing ER{alpha}{Delta}185–251. However, ER{alpha}{Delta}250–274 was incapable of inducing Src activation by E2. Coimmunoprecipitation studies of the interaction between wild-type or mutant ER{alpha} and the p85 subunit of PI3 kinase were also performed (Fig. 9Go, C and D). As anticipated, p85 was minimally associated with wild-type receptor in the absence of ligand and E2 promoted the interaction. In contrast, there was marked binding of p85 to ER{alpha}{Delta}250–274 in the absence of ligand, and the addition of E2 actually caused a decrease in the interaction between the two proteins. Cells expressing ER{alpha}{Delta}185–251 also displayed binding of the mutant receptor to p85 in the absence of ligand, and the addition of E2 had no effect.



View larger version (31K):
[in this window]
[in a new window]
 
Fig. 9. ER{alpha} Domains Involved in Nuclear Localization and DNA Binding Modify Src Activation and ER{alpha}-PI3 Kinase Interaction

COS-7 cells were transiently transfected with cDNA for either wild-type ER{alpha}, ER{alpha}{Delta}250–274, or ER{alpha}{Delta}185–251. Forty-eight hours later, the cells were treated with 10–8 M E2 for 0–15 min, and cell lysates were obtained and analyzed by immunoblot using anti phospho-Tyr416 Src polyclonal antibody (pSrc) or anti-Src monoclonal antibody. Representative findings are shown in A. Cumulative results for Src phosphorylation (normalized to total Src) relative to basal (no E2 treatment) for three independent experiments are in B. In separate experiments, postnuclear supernatants (PNS) were obtained after E2 treatment and the interaction between ER{alpha} and the p85 subunit of PI3 kinase was assessed by coimmunoprecipitation and immunoblot analyses for p85 and ER{alpha}. Representative findings are shown in C. Cumulative results for p85 coimmunoprecipitation (normalized for amount of ER{alpha} immunoprecipitated) relative to basal (no E2 treatment) for three independent experiments are in D. Values in B and D are mean ± SEM. *, P < 0.05 vs. basal.

 

    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
NO production in response to the nongenomic activation of eNOS is critically involved in the cardiovascular protective actions of estrogen (1, 3). This process is mediated by PM-associated ER, which are coupled to the enzyme in endothelial cell caveolae/rafts (5, 12). In the present study, we have investigated the proximal events in this process by evaluating the role of ER{alpha} domains that are known to be critically involved in the classical nuclear functions of the receptor. We have shown that although certain domains mediating nuclear actions are most likely not involved in nongenomic activation of eNOS, other ER{alpha} domains relevant to nuclear function also modulate specific components of the rapid signaling events upstream of the enzyme.

The classical nuclear actions of ER{alpha} entail receptor dimerization, which is essential for stable binding of the receptor to EREs (6, 8). In the past, this process has been evaluated primarily from the context of DNA binding (20, 24). To study the potential dimerization of PM-associated ER{alpha}, we developed a strategy involving cross-linking and immunoblot analysis. Using forms of ER{alpha} with intact dimerization signals but different molecular weights, antibodies to the receptor-detected protein species, which were twice the size of monomers in all instances when cells were exposed to estrogen and cross-linker. Effective detection of dimer formation was further confirmed by loss of the dimer signal in studies of ER{alpha}L511R. Although the proportion of receptors undergoing dimerization is most likely not reliably quantitated in this manner, the presence or absence of the process is demonstrable. With this approach, we showed that estrogen causes the dimerization of PM-associated ER{alpha}. The requirement for dimerization in ER{alpha} modulation of eNOS activity was then tested, and we found that eNOS stimulation in either intact cells or in isolated PMs was induced by both wild-type ER{alpha} and ER{alpha}L511R, which has attenuated dimerization. In fact, there was modestly greater eNOS activation by ER{alpha}L511R vs. wild-type receptor that was equivalently evident in intact cells and isolated PMs. These observations indicate that dimerization does not play a significant role in ER{alpha} modulation of eNOS activity. The parallel findings in cells and PMs further suggest that E2-induced eNOS stimulation occurs primarily at the PM and not in the Golgi apparatus (25).

Our finding of E2-induced dimerization of membrane ER{alpha} is consistent with the recently reported observations of Razandi et al. (26). However, our finding of a complete lack of dependence on dimerization for eNOS activation by ER{alpha} in COS-7 cells contrasts with their observations in CHO cells of dependence on dimerization for Akt phosphorylation, which is upstream of eNOS phosphorylation (26). This disparity may be related to the differing cellular contexts of the two investigations, including the differences in ER{alpha} coupling to G{alpha}i, which is required for eNOS activation by ER{alpha} in endothelial cells and which is demonstrable in the COS-7 but not in the CHO reconstitution system (19, 26).

Another critical aspect of classical genomic action of ER{alpha} is the localization of the receptor in the nucleus, which is mediated by three NLS domains (21). Because the short-term actions of ER{alpha} are characterized instead by either the activation of receptors already localized to the cell surface or the recruitment of receptors to the PM (12, 17, 27), we originally hypothesized that the principal NLS domains, NLS2 and NLS3, would not be required for ER{alpha} targeting and coupling to eNOS on the membrane. The NLS2,3-deficient mutant form of ER{alpha}, ER{alpha}{Delta}250–274, was localized to the PM in a manner comparable with wild-type receptor. This finding indicates that protein folding occurred well enough to pass the quality control mechanisms of the endoplasmic reticulum. However, in marked contrast to wild-type ER{alpha}, ER{alpha}{Delta}250–274 did not mediate eNOS activation in either intact cells or isolated PMs. One potential explanation was that ER{alpha}{Delta}250–274 may not be targeted to caveolae to reside within the domain to be coupled to eNOS. This possibility was ruled out in experiments assessing the distribution of the mutant receptor within the PM, which revealed targeting to caveolae that was comparable to that of wild-type receptor. We then determined whether either of the two key phosphorylation events coupling ER activation to eNOS were disrupted by the deletion of NLS2 and NLS3. Whereas wild-type ER{alpha} mediated both E2-induced erk activation and eNOS phosphorylation at serine 1179, which is critical to enzyme activation (3), both of these processes were absent in cells expressing ER{alpha}{Delta}250–274. The level of phosphorylation of serine 1179 is positively regulated by Akt, and it is negatively regulated by the phosphatase PP2A (28). To differentiate between potential alterations in Akt and PP2A action, additional studies were performed in cells coexpressing a constitutively active form of Akt. In this context, eNOS phosphorylation at least comparable with that observed with E2 activation of wild-type receptor was observed in ER{alpha}{Delta}250–274-expressing cells. This finding makes an alteration in PP2A activity less likely, and instead suggests that ER{alpha}{Delta}250–274 is incapable of activating PI3kinase-Akt kinase signaling. Constitutively, active Akt did not impact upon erk phosphorylation, suggesting that erk signaling is independent of Akt in this paradigm. In ongoing studies of ER{alpha} modulation of the cyclooxygenase-1 promoter in the same model system, we have observed that ER{alpha}{Delta}250–274 has equivalent potency as wild-type receptor (Gibson, L. L., L. Hahner, S. Osborne-Lawrence, Z. German, K. K. Wu, K. L. Chambliss, and P. W. Shaul, unpublished observation). Thus, the mutant receptor is indeed functional in another context, and a subpopulation is effectively localized in caveolae, but it is entirely incapable of erk and PI3 kinase/Akt kinase-mediated signaling on the cell surface.

A third important feature of classical nuclear action of ER{alpha} is direct binding of the receptor, via the DNA binding domain, to EREs on target genes (6). We originally hypothesized that the DNA binding domain would not be needed for cell surface ER{alpha} localization and coupling to eNOS, and found that wild-type receptor and the ER{alpha}{Delta}185–251 mutant displayed equivalent targeting to PM. As for ER{alpha}{Delta}250–274, this observation indicates that the folding of ER{alpha}{Delta}185–251 was sufficient enough to allow the protein to be released from the endoplasmic reticulum. However, whereas wild-type ER{alpha} invoked eNOS activation in both intact cells and isolated PMs, ER{alpha}{Delta}185–251was entirely inactive. This was not explained by ineffective targeting of the mutant to the caveolae fraction of the PM. We then determined whether erk and eNOS phosphorylation were stimulated by ER{alpha}{Delta}185–251. In contrast with wild-type receptor, which mediated both processes, and ER{alpha}{Delta}250–274, which stimulated neither, ER{alpha}{Delta}185–251 caused erk activation equivalent to that seen with wild-type receptor but eNOS phosphorylation was completely absent. However, eNOS phosphorylation at least comparable with that observed with E2 activation of wild-type receptor was evident in ER{alpha}{Delta}185–251-expressing cells after coexpression of constitutively active Akt kinase. These cumulative observations indicate that components within the DNA binding domain of ER{alpha} impact uniquely upon processes regulating PI3 kinase-Akt kinase activation.

To further determine how deletion of NLS2/NLS3 or the DNA binding region attenuate PI3 kinase-Akt kinase activation by ER{alpha}, experiments were performed to assess how these domains impact on the association or activation of Src and PI3 kinase. We found that loss of the DNA binding domain does not alter the capacity for E2 to activate Src in parallel with the retained capacity to activate erk, whereas ligand-induced association of PI3 kinase with the receptor and eNOS phosphorylation do not occur. In fact, there was ligand-independent association of p85 with the ER{alpha} mutant lacking the DNA binding domain that was unchanged with E2. These findings indicate that E2-ER{alpha}-induced Src activation alone is not sufficient to promote dynamic PI3 kinase recruitment to a complex with ER{alpha} and its activation and resultant downstream phosphorylation events. They also indicate that sequences within the DNA binding domain are important to the modulation of PI3 kinase, possibly by binding an accessory protein that prevents PI3 kinase interaction with the receptor until ligand activation occurs. We also found that loss of NLS2/NLS3 prevents Src and erk activation and it perturbs ligand-induced PI3 kinase recruitment, causing an interaction that is E2 independent and actually markedly attenuated by the ligand. Src association with ER{alpha} entails the A/B domain, which binds MNAR (modulator of nongenomic activity of ER), which interacts with the SH3 domain of Src, and phosphotyrosine 537 in the E region, which interacts with the SH2 domain of Src (29). As such, the loss of NLS2/NLS3 is not likely to disrupt Src activation by preventing its interaction with the receptor. It is most likely through other mechanisms that NLS2/NLS3 of ER{alpha} are critical to the regulation of Src and PI3 kinase, which play important roles not only in eNOS regulation on the membrane (3), but in ER{alpha} nuclear actions (30). Based on these detailed new findings, additional studies are now warranted to identify membrane-associated or cytosolic proteins interacting with NLS2/NLS3 and the DNA binding domain, and to further delineate the discrete domains of ER{alpha} that are involved.

The present findings that domains within regions C and D of ER{alpha} are required for effective signaling to erk, PI3 kinase/Akt kinase, and eNOS should be interpreted in the context of previously reported observations related both directly to eNOS and to other membrane-initiated actions of estrogen. It has been found that certain endothelial cells express an ER{alpha} variant designated ER46 that is a truncated form of the receptor lacking the N-terminal A and B regions, and that ER46 is capable of modulating eNOS activation (31). ER46 contains the C, D, and E regions, and the present results indicate that ligand binding and coupling to erk and PI3 kinase would likely be conserved in such a construct. Consistent with the current observations, it has also been found in studies limited to the activation of erk that such function is retained in an A/B deletion mutant of ER{alpha} as well as in a mutant lacking the C region (32). Furthermore, the present finding that ER{alpha} mutants lacking domains within the C and D regions are properly targeted to PM caveolae is in agreement with the recent report that serine 533 within the remaining E region is important to membrane localization of the receptor (32). However, despite all of these consistencies, the currently observed inability of the mutant of ER{alpha} deficient in NLS2 and NLS3 in regions C and D to activate erk is inconsistent with previous reports that the E domain alone is capable of doing so. It may be relevant that the latter observations were made with directed targeting of the E domain to PM (22, 23, 33). At any rate, paralleling the previous investigations that revealed functional domains of ER{alpha} mediating various aspects of nuclear responses (6), information is now emerging regarding the domains which are required for nongenomic, membrane initiated actions of the receptor. Further dissection of the nongenomic functional domains will be critical to our ultimate understanding of the diverse processes regulated by estrogen in multiple cell types.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Cell Culture and Transfection
Experiments were performed in COS-7 cells (American Type Culture Collection) grown in DMEM (Life Technologies, Inc., Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum plus 200 U/ml penicillin and 200 µg/ml streptomycin. COS-7 cells were employed because they do not constitutively express estrogen receptors, and they do not display 17ß-estradiol (E2)-stimulated eNOS activity when transfected with eNOS alone (4).

The PM distribution and function of wild-type human ER{alpha} or mutant forms of the receptor was tested 48 h after transient transfection using previously reported approaches (5). Studies focused on a mutant of ER{alpha} with a substitution within the dimerization domain (ER{alpha}L511R) (20), a deletion mutant lacking the two primary NLS, NLS 2 and 3 (ER{alpha}{Delta}250–274), and a deletion mutant lacking the DNA binding domain (ER{alpha}{Delta}185–251). The ER{alpha}L511R mutant was generated by PCR amplification of human ER{alpha} cDNA with primers 5'-GGTCCACCTTCTAGAATGTG-3' and 5'-TGTGCCTGATGTGGGAGCGG-3' in one reaction and primers 5'-CCGCTCCCACATCAGGCACA-3' and 5'-TAGAAGGCACAGTCGAGGCTG-3' in a separate reaction. The two PCR products were combined and reamplified with 5'-GGTCCACCTTCTAGAATGTG-3' and 5'-TAGAAGGCACAGTCGAGGCTG-3'. The resulting product was ligated into wild-type ER{alpha} cDNA in pCDNA3.1 using the XbaI and EcoRV restriction sites. The ER{alpha}{Delta}250–274 mutant was constructed by ligating two PCR products generated from wild-type human ER{alpha} cDNA template. The upstream PCR product was amplified using primers both directed to ER{alpha} (sense primer 5'-GCCGCCTACGAGTTCAACGC-3' and antisense primer 5'-CCATCGATTCCCACTTCGTAGCATTTGC-3'), whereas the downstream PCR product was made using sense primer 5'-GGATCGATGAGGGCAGGGGTGAAGTGGG-3' directed to the ER{alpha} D domain and antisense primer 5-TAGAAGGCACAGTCGAGGCTG-3' anchored in the pCDNA3.1 vector. The PCR products were ligated to each other using the ClaI site, which was engineered into the primers, and into the ER{alpha} wild-type cDNA construct in pCDNA3.1 at the SacII restriction site upstream and the EcoRV site located downstream in the vector. The resulting construct is comparable with HE257G (21). ER{alpha}{Delta}185–251, which is equivalent to HE11 (21), was kindly provided by Dr. Michael Mendelsohn (Molecular Cardiology Research Institute, New England Medical Center Hospitals, Inc., Tufts University School of Medicine, Boston, MA). All mutants were sequenced to verify structure.

To assess the nuclear function of the constructs, E2-induced transcriptional transactivation was evaluated by cotransfection with a luciferase reporter plasmid that contained either three exact copies of the Xenopus vitellogenin ERE, designated 3ERE-Luc, as previously reported (5), or two copies of ERE within the native context of the vitellogenin promoter (2ERE-Luc) (34). The latter reporter plasmid, which was necessary to effectively assess the requirement for receptor dimerization, was kindly provided by Dr. David Shapiro in the Department of Biochemistry, University of Illinois at Urbana-Champaign. After transfection, cells were placed in either phenol red-free, estrogen-free media, phenol red-free media containing 10–8 M E2, or phenol red-free media containing E2 plus 10–5 M ICI 182,780 for 48 h, and reporter activity was measured. Cells were cotransfected with a plasmid containing simian virus 40-driven ß-galactosidase to normalize for transfection efficiency (35).

To evaluate the capacity of the constructs to activate eNOS, COS-7 cells were cotransfected with bovine eNOS cDNA (36) and either wild-type or mutant forms of ER{alpha}. Comparable expression of the constructs was confirmed by immunoblot analysis. Coimmunofluorescence experiments revealed that transfection efficiency was approximately 20% for either ER{alpha} or eNOS, and that the majority of transfected cells expressed both the receptor and enzyme. In selected experiments, the cells were also cotransfected with an Akt mutant generated by fusing a myrisoylation signal to its amino terminus (AktMyr), which is membrane bound and constitutively active (37). AktMyr was kindly provided by Dr. Michael Quon (Diabetes Unit, Laboratory of Clinical Investigation, National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, MD).

Subcellular Fractionation
To study the subcellular distribution of wild-type and mutant forms of ER{alpha} and to localize their function, subfractionation was performed on transfected COS-7 cells as previously described (12). The purity of the PM fraction obtained has been previously confirmed by measurements of alkaline phosphatase (PM), galactosyl transferase (Golgi) and reduced nicotinamide adenine dinucleotide phosphate cytochrome C reductase (endoplasmic reticulum) activity (38). All fractionation steps were done in the absence of exogenous calcium. Successful isolation of the caveolae subfraction of the PM was confirmed by immunoblot analyses for the caveolae marker protein caveolin-1 and the noncaveolae protein, receptor for activated C-kinase (RACK1) (39). The protein contents of all samples were determined by the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA) or by the method of Bradford (40). In experiments assessing the targeting of wild-type and mutant receptors to PM and CM, immunoblot analyses were quantitated using LabWorks Image Acquisition and Analysis Software (BioImaging Systems, Upland, CA). Receptor distribution was adjusted for the efficiency of recovery of PM and CM calculated by comparing the amount of caveolin in the membrane fractions vs. the whole cell lysate. Quantitation experiments were performed on three separate preparations of each construct.

Immunoblot Analyses
Immunoblot analyses were performed using standard procedures to evaluate the abundance and distribution of wild-type and mutant forms of ER{alpha}, eNOS, caveolin-1, and RACK1 (41). Equivalence of protein loads was confirmed by amido black staining (Sigma Chemical Co., St. Louis, MO). The analyses of wild-type or mutant ER{alpha} used a mouse monoclonal antibody directed against amino acids 495–595 of ER{alpha} (2.5 µg/ml, AER320; Labvision, Fremont, CA,) or antibody AER611 (2.5 mg/ml, Labvision), which we have determined recognizes an epitope in the N-terminal 78 amino acids of the receptor. Monoclonal antiserum to eNOS (0.25 µg/ml) and polyclonal antiserum to caveolin-1 (0.05 mg/ml) or RACK1 (0.1 µg/ml) were from Transduction Laboratories (Lexington, KY). To assess erk activation in response to E2, COS-7 cells were exposed to the hormone (10–8 M) for 0–20 min 48 h after transfection, whole cell lysates were obtained, and immunoblot analysis was performed with anti-ERK2 monoclonal antibody (Upstate Biotechnology, Inc., Lake Placid, NY) and anti-perk polyclonal antibody (Promega Corp., Madison, WI). In a similar manner, eNOS phosphorylation was evaluated after 0–20 min exposure to 10–8 M E2 by immunoblot analysis using anti-phospho-serine-1179 eNOS polyclonal antibody (Cell Signaling Technology, Beverly, MA) (37). Src phosphorylation was also assessed after 0–10 min exposure to 10–8 M E2 by immunoblot analysis using anti-phospho-tyrosine-416 Src polyclonal antibody (Cell Signaling Technology) and anti-Src monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA).

Assessment of Receptor Dimerization
ER{alpha} dimerization was evaluated in COS-7 cells expressing ER{alpha} constructs using the cell-permeable cross-linking agent l-ethyl-3-[3-(dimethylamino) propyl] carbodiimide (EDAC, Pierce Biochemicals, Rockford, IL). Experiments were performed with wild-type receptor, ER{alpha}L511R, ER{alpha}{Delta}185–251, or an N-terminal deletion mutant lacking residues 1–175 (ER{alpha}{Delta}1–175) kindly provided by Dr. Michael Mendelsohn (42, 43). Forty-eight hours after transfection, cells were exposed to buffer or E2 (10–8 M) for 0–24 h and either vehicle or 10 mM EDAC for 60 min at 22 C, and whole cell lysates or purified PM fractions were obtained. Immunoblot analysis was then performed for ER{alpha}. Results shown are representative of three independent experiments.

NOS Activation
eNOS activation was assessed in intact COS-7 cells transfected with cDNAs for the enzyme and for ER{alpha} constructs by measuring 3H-L-arginine conversion to 3H-L-citrulline, using previously reported methods (12). Adherent cells grown in six-well plates were placed in L-arginine-deficient, serum-free endothelial-SFM growth media (Life Technologies, Inc.) for 2 h, and then preincubated in PBS (pH 7.4) containing 120 mM NaCl, 4.2 mM KCl, 2.5 mM CaCl2, 1.3 mM MgSO4, 7.5 mM glucose, 10 mM HEPES, 1.2 mM Na2HPO4, and 0.37 mM KH2PO4 for 15 min at 37 C. The ensuing 15 min incubation for eNOS activity was initiated by replacing the preincubate with PBS containing 1.5 µCi/ml 3H-L-arginine. After 15 min, the reaction was stopped by adding 1 N trichloroacetic acid, the cells were freeze-fractured in liquid nitrogen and scraped with a rubber spatula, the contents of each well were ether extracted, and the 3H-L-citrulline generated was isolated using Dowex AG50WX-8 columns and quantified by liquid scintillation spectroscopy.

To evaluate eNOS activation by estrogen, 3H-L-arginine conversion to 3H-L-citrulline was measured in intact cells either under basal conditions or in the presence of 10–8 M E2 during 15-min incubations. In previous experiments, the effect of E2 was demonstrable within 5 min, the maximal response was obtained at 10–8 M, and the threshold concentration was 10–10 M (4). The role of estrogen receptors in eNOS activation was confirmed by the addition of ICI 182,780 (10–5 M) during the 15 min incubation for NOS activity. In control experiments, E2 did not stimulate eNOS in COS-7 cells expressing the enzyme alone. Both basal and stimulated NOS activity were completely inhibited by 2.0 mM nitro-L-arginine methyl ester. NOS activity was expressed relative to basal levels, which are designated as 100%, in the same six-well plate. All findings were confirmed in at least three independent studies.

In addition to being localized and modulated on the PM, there is evidence that eNOS can be phosphorylated and stimulated in the Golgi complex (25). Recent studies also suggest that estrogen can cause the activation of Akt kinase in the Golgi apparatus (44). To provide a focused evaluation of PM eNOS regulation by PM-associated ER{alpha}, eNOS activation was assessed not only in whole cells but also in purified PMs reconstituted in 50 mM Tris HCl buffer (pH 7.4) with 0.1 mM EDTA, 10 µg/ml pepstatin A, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 10 µg/ml N-p-tosyl-L-lysine chloromethyl ketone, 10 nM phenylmethylsulfonyl fluoride, 3 mM dithiothreitol, and 10 mM 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (12). Membranes (10 µg) were incubated with 2.0 µCi/ml of 3H-L-arginine and 2 M cold L-arginine, and citrulline generation was evaluated over 60 min at 37 C. The assay was terminated by the addition of 400 µl of 40 mM HEPES buffer (pH 5.5), with 2 mM EDTA and 2 mM EGTA. 3H-L-citrulline generated was isolated and quantified as described for the intact cell experiments. The variability in basal activity in isolated membranes is typically ± 10%. All observations were confirmed in a minimum of three separate studies.

To determine the effect of estrogen on eNOS in the isolated membranes, incubations for activity were performed in the absence or presence of 10–8 M E2. In control experiments, E2 did not stimulate eNOS in membranes from COS-7 cells lacking ER{alpha}. To confirm the role of membrane-associated ER{alpha} in E2 responses, studies were done in the absence or presence of ICI 182,780 (10–5 M). NOS activity in all membrane samples was fully inhibited by 2 mM nitro-L-arginine methyl ester.

Coimmunoprecipitation
The immunoprecipitation of ER was performed by methods described previously (19). Briefly, COS-7 cells transfected with wild-type ER or mutant forms of the receptor 24 h earlier were placed in DMEM without serum for another 24 h. The cells were treated with vehicle or E2 (10–8 M) for 0–15 min and the postnuclear supernatants were isolated. The wild-type or mutant receptors were immunoprecipitated from 200 µg of postnuclear supernatant using monoclonal ER antibody (AER320; Labvision). Coimmunoprecipitated p85 subunit of PI3 kinase was detected using polyclonal anti-p85 antibody (Santa Cruz Biotechnology, Inc.).

Statistical Analysis
Differences in observations between treatment groups were evaluated by one-way ANOVA after establishing equivalence of variances and normal distribution of data. The level of significance of differences between mean values was assessed by the Student-Newman-Keuls method. Values shown are mean ± SEM, with n = 3 or more. Significance was accepted at the 0.05 level of probability.



View larger version (32K):
[in this window]
[in a new window]
 
Fig. 6. ER{alpha} Domains Involved in Receptor Nuclear Localization and DNA Binding Are Not Required for Targeting to Caveolae

COS-7 cells were transiently transfected with cDNA for wild-type ER{alpha}, ER{alpha}{Delta}250–274, or ER{alpha}{Delta}185–251. Forty-eight hours later, whole cell lysates (WC), PM, and CM subfractions of the PM were isolated, and receptor distribution was assessed by immunoblot analysis. Caveolin-1 (Cav-1) protein abundance were also determined to assess fraction separation. Findings shown are representative of three independent studies.

 

    ACKNOWLEDGMENTS
 
We are indebted to Marilyn Dixon for preparing this manuscript, and to Michael Mendelsohn for his critical assessment of the paper.


    FOOTNOTES
 
This work was supported by National Institutes of Health Grants HL58888, HL53546, and HD30276 (to P.W.S.). The project was also supported in part by the Scientist Development Program of the American Heart Association (to C.M.), by the Crystal Charity Ball Center for Pediatric Critical Care Research, and by the Lowe Foundation.

Current address for L.S.: Department of Pediatrics, Yale University School of Medicine, P.O. Box 208064, 333 Cedar Street, New Haven, Connecticut 06520.

First Published Online October 14, 2004

1 K.L.C. and L.S. contributed equally to this work. Back

Abbreviations: CM, Caveolae membrane; E2, 17ß-estradiol; EDAC, l-ethyl-3-[3-(dimethylamino) propyl] carbodiimide; eNOS, endothelial nitric oxide synthase; ER, estrogen receptor; ERE, estrogen response element; NLS, nuclear localization signal; NO, nitric oxide; PI3 kinase, phosphoinositide 3-kinase; PM, plasma membrane; RACK1, receptor for activated C-kinase.

Received for publication January 9, 2004. Accepted for publication October 5, 2004.


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 

  1. Mendelsohn ME, Karas RH 1999 The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801–1811[Free Full Text]
  2. Simoncini T, Genazzani AR 2000 Direct vascualr effects of estrogens and selective estrogen receptor modulators. Curr Opinion Obstet Gynecol 12:181–187[CrossRef][Medline]
  3. Chambliss KL, Shaul PW 2002 Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 23:665–686[Abstract/Free Full Text]
  4. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW 1999 Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 103:401–406[Abstract/Free Full Text]
  5. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME, Shaul PW 2002 ERß has nongenomic action in caveolae. Mol Endocrinol 16:938–946[Abstract/Free Full Text]
  6. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P 1987 Functional domains of the human estrogen receptor. Cell 51:941–951[Medline]
  7. Aumais JP, Lee HS, Lin R, White JH 1997 Selective interaction of hsp90 with an estrogen receptor ligand-binding domain containing a point mutation. J Biol Chem 272:12229–12235[Abstract/Free Full Text]
  8. Sanchez R, Nguyen D, Rocha W, White JH, Mader S 2002 Diversity in the mechanisms of gene regulation by estrogen receptors. Bioessays 24:244–254[CrossRef][Medline]
  9. Moggs JG, Orphanides G 2001 Estrogen receptors: orchestrators of pleiotropic cellular responses. EMBO Rep 2:775–781[Abstract/Free Full Text]
  10. Watson CS, Gametchu B 1999 Membrane-initiated steroid actions and the proteins that mediate them. Proc Soc Exp Biol Med 220:9–19[Abstract]
  11. Kelly MJ, Levin ER 2001 Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab 12:152–156[CrossRef][Medline]
  12. Chambliss KL, Yuhanna IS, Mineo C, Liu P, German Z, Sherman TS, Mendelsohn ME, Anderson RG, Shaul PW 2000 Estrogen receptor {alpha} and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circ Res 87:E44–E52
  13. Shaul PW 2002 Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol 64:749–774[CrossRef][Medline]
  14. Venema RC 2002 Post-translational mechanisms of endothelial nitric oxide synthase regulation by bradykinin. Int Immunopharmacol 2:1755–1762[CrossRef][Medline]
  15. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, Sessa WC, Bender JR 2000 Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 87:677–682[Abstract/Free Full Text]
  16. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK 2000 Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538–541[CrossRef][Medline]
  17. Simoncini T, Rabkin E, Liao JK 2003 Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arterioscler Thromb Vasc Biol 23:198–203[Abstract/Free Full Text]
  18. Haynes MP, Li L, Sinha D, Russell KS, Hisamoto K, Baron R, Collinge M, Sessa WC, Bender JR 2003 Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J Biol Chem 278:2118–2123[Abstract/Free Full Text]
  19. Wyckoff MH, Chambliss KL, Mineo C, Yuhanna IS, Mendelsohn ME, Mumby SM, Shaul PW 2001 Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through G{alpha}(i). J Biol Chem 276:27071–27076[Abstract/Free Full Text]
  20. Fawell SE, Lees JA, White R, Parker MG 1990 Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor. Cell 60:953–962[Medline]
  21. Ylikomi T, Bocquel MT, Berry M, Gronemeyer H, Chambon P 1992 Cooperation of proto-signals for nuclear accumulation of estrogen and progesterone receptors. EMBO J 11:3681–3694[Abstract]
  22. Kousteni S, Bellido T, Plotkin LI, O’Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC 2001 Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104:719–730[Medline]
  23. Razandi M, Oh P, Pedram A, Schnitzer J, Levin ER 2002 ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol Endocrinol 16:100–115[Abstract/Free Full Text]
  24. Lees JA, Fawell SE, White R, Parker MG 1990 A 22-amino-acid peptide restores DNA-binding activity to dimerization-defective mutants of the estrogen receptor. Mol Cell Biol 10:5529–5531[Medline]
  25. Fulton D, Fontana J, Sowa G, Gratton JP, Lin M, Li KX, Michell B, Kemp BE, Rodman D, Sessa WC 2002 Localization of endothelial nitric-oxide synthase phosphorylated on serine 1179 and nitric oxide in Golgi and plasma membrane defines the existence of two pools of active enzyme. J Biol Chem 277:4277–4284[Abstract/Free Full Text]
  26. Razandi M, Pedram A, Merchenthaler I, Greene GL, Levin ER 2004 Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol 18:2854–2865[Abstract/Free Full Text]
  27. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ 2002 Linkage of rapid estrogen action to MAPK activation by ER{alpha}-Shc association and Shc pathway activation. Mol Endocrinol 16:116–127[Abstract/Free Full Text]
  28. Greif DM, Kou R, Michel T 2002 Site-specific dephosphorylation of endothelial nitric oxide synthase by protein phosphatase 2A: evidence for crosstalk between phosphorylation sites. Biochemistry 41:15845–15853[CrossRef][Medline]
  29. Barletta F, Wong CW, McNally C, Komm BS, Katzenellenbogen B, Cheskis BJ 2004 Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. Mol Endocrinol 18:1096–1108[Abstract/Free Full Text]
  30. Feng W, Webb P, Nguyen P, Liu X, Li J, Karin M, Kushner PJ 2001 Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway. Mol Endocrinol 15:32–45[Abstract/Free Full Text]
  31. Li L, Haynes MP, Bender JR 2003 Plasma membrane localization and function of the estrogen receptor {alpha} variant (ER46) in human endothelial cells. Proc Natl Acad Sci USA 100:4807–4812[Abstract/Free Full Text]
  32. Razandi M, Alton G, Pedram A, Ghonshani S, Webb P, Levin ER 2003 Identification of a structural determinant necessary for the localization and function of estrogen receptor {alpha} at the plasma membrane. Mol Cell Biol 23:1633–1646[Abstract/Free Full Text]
  33. Razandi M, Pedram A, Park ST, Levin ER 2003 Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 278:2701–2712[Abstract/Free Full Text]
  34. Chang TC, Nardulli AM, Lew D, Shapiro DJ 1992 The role of estrogen response elements in expression of the Xenopus laevisvitellogenin B1 gene. Mol Endocrinol 6:346–354[Abstract]
  35. MacRitchie AN, Jun SS, Chen Z, German Z, Yuhanna IS, Sherman TS, Shaul PW 1997 Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium. Circ Res 81:355–362[Abstract/Free Full Text]
  36. Lamas S, Marsden PA, Li GK, Tempst P, Michel T 1992 Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci USA 89:6348–6352[Abstract/Free Full Text]
  37. Mineo C, Yuhanna IS, Quon MJ, Shaul PW 2003 High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 278:9142–9149[Abstract/Free Full Text]
  38. Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ 1999 Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem 274:32512–32519[Abstract/Free Full Text]
  39. Mineo C, Ying YS, Chapline C, Jaken S, Anderson RG 1998 Targeting of protein kinase C{alpha} to caveolae. J Cell Biol 141:601–610[Abstract/Free Full Text]
  40. Bradford MM 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254[CrossRef][Medline]
  41. Shaul PW, Smart EJ, Robinson LJ, German Z, Yuhanna IS, Ying Y, Anderson RG, Michel T 1996 Acylation targets emdothelial nitric-oxide synthase to plasmalemmal caveolae. J Biol Chem 271:6518–6522[Abstract/Free Full Text]
  42. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS 1994 Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 269:4458–4466[Abstract/Free Full Text]
  43. McInerney EM, Katzenellenbogen BS 1996 Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation. J Biol Chem 271:24172–24178[Abstract/Free Full Text]
  44. Sasaki K, Sato M, Umezawa Y 2003 Fluorescent indicators for Akt/protein kinase B and dynamics of Akt activity visualized in living cells. J Biol Chem 278:30945–30951[Abstract/Free Full Text]